Literature DB >> 6315333

Drugs for the prevention of peptic ulcer recurrence.

D W Piper.   

Abstract

The treatment of chronic peptic ulcer involves the treatment of acute exacerbations and the complications, and the prevention of ulcer recurrence. Several drugs accelerate the initial healing of ulcer and include the H2-receptor antagonists (cimetidine and ranitidine), colloidal bismuth, sucralfate, pirenzepine, carbenoxolone sodium, prostaglandins, high dose antacids and trimipramine. The long term management of ulcer involves the use of drugs and, in selected patients, surgery. Drugs used in this context include H2-receptor antagonists, pirenzepine, sucralfate and probably prostaglandins when further trial evidence is available. Regimens of long term drug treatment include intermittent treatment and maintenance treatment. The former consists of no active treatment after the ulcer is healed and the treatment of each acute exacerbation when it occurs, this treatment involving any one of the several drug routines mentioned above. If exacerbations are frequent (i.e. more than 2 to 3 years), maintenance therapy with H2-receptor antagonists, pirenzepine or sucralfate is advised. If the ulcer recurs despite long term treatment, it may be healed again using the healing dose of the above agents, and maintenance therapy recommenced if the remission induced by maintenance therapy was several years. If the remission was short, surgery should be advised.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315333     DOI: 10.2165/00003495-198326050-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  52 in total

1.  Double-blind placebo-controlled evaluation of one year therapy with sucralfate in healed duodenal ulcer.

Authors:  M G Moshal; J M Spitaels; G L Manion
Journal:  Scand J Gastroenterol Suppl       Date:  1983

2.  Reminiscences of the development of cimetidine.

Authors:  W A Duncan; M E Parsons
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

3.  Cimetidine interaction with carbamazepine.

Authors:  N Telerman-Toppet; M E Duret; C Cöers
Journal:  Ann Intern Med       Date:  1981-04       Impact factor: 25.391

4.  Pirenzepine selectively inhibits gastric acid secretion: a comparative pharmacological study between pirenzepine and seven other antiacetylcholine drugs.

Authors:  B V Heathcote; M Parry
Journal:  Scand J Gastroenterol Suppl       Date:  1980

5.  Prophylactic effect of cimetidine in duodenal ulcer disease.

Authors:  E Gudmand-Høyer; K B Jensen; E Krag; J Rask-Madsen; I Rahbek; S J Rune; H R Wulff
Journal:  Br Med J       Date:  1978-04-29

6.  Endoscopic evaluation of the effect of sucralfate therapy and other clinical parameters on the recurrence rate of gastric ulcers.

Authors:  T Miyake; J Ariyoshi; T Suzaki; M Oishi; M Sakai; S Ueda
Journal:  Dig Dis Sci       Date:  1980-01       Impact factor: 3.199

7.  Development and characteristics of sucralfate.

Authors:  R Nagashima
Journal:  J Clin Gastroenterol       Date:  1981       Impact factor: 3.062

8.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

9.  Controlled trial of maintenance cimetidine treatment in healed duodenal ulcer: short and long-term effects.

Authors:  M W Dronfield; A J Batchelor; W Larkworthy; M J Langman
Journal:  Gut       Date:  1979-06       Impact factor: 23.059

10.  A comparison of a series of newer anticholinergic agents with atropine as regards their effect on saliva flow and gastric secretion in man.

Authors:  D W PIPER; M C STIEL
Journal:  Gut       Date:  1962-03       Impact factor: 23.059

View more
  3 in total

1.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

2.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of famotidine.

Authors:  H Echizen; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.